The risk of symptomatic deep vein thrombosis (DVT) among patients with non-small cell lung cancer (NSCLC) has not been well studied. We conducted a retrospective cohort study of patients with NSCLC to determine the incidence of DVT and to characterize predictors of DVT in patients with NSCLC. Methods: The pulmonary oncology database of the Sir Mortimer B. Davis-Jewish General Hospital contains prospectively collected clinical data on lung cancer patients since January 1, 1997. We identified all consecutive patients with histologically confirmed new diagnoses of NSCLC between January 1, 1997 and December 31, 2004, and we determined the occurrence of an objectively defined DVT. Data on clinical and tumor characteristics were collected and compared among patients with DVT and patients without DVT. Results: Of the 493 NSCLC patients included in the cohort for a total of 634 person-years, 67 (13.6%) patients developed objectively confirmed DVTs, with an incidence of 110 cases (95% confidence interval [CI] 80, 130) per 1000 person-years. An adjusted multivariable regression analysis showed that advanced stage (rate ratio [RR] 2.63, 95% CI 1.38, 5.00) and male sex (RR 1.75, 95% CI 1.03-2.94) were independent predictors of DVT. Conclusions: Our results show a high incidence of DVT in NSCLC patients. Advanced stage and, to a lesser extent, male sex, are important predictors of DVT. Trials to evaluate the use of prophylactic anticoagulant treatments in patients with NSCLC should be conducted.
D
eep vein thrombosis (DVT) is a well-recognized complication of cancer and is estimated to occur in 4% to 17% of patients with underlying malignancies. [1] [2] [3] [4] It is an important health problem in cancer patients and is associated with significant morbidity and mortality. Specifically, cancer patients with thrombosis have a four-to sixfold higher risk of dying after an acute thrombotic event than do patients without cancer. 5 Furthermore, patients with cancer and thrombosis have a two-to threefold lower survival rate than those with cancer and without thrombosis. 6 It is believed that the complications of venous thrombosis, such as recurrent thrombosis or fatal pulmonary embolism, do not entirely explain the decreased survival rate, and that perhaps the tumors of patients with thrombosis are more aggressive than those of patients without thrombosis.
Among patients with malignancies presenting with DVT, lung, prostate, breast, and colorectal cancer are the most commonly identified; collectively, they comprise approximately 10% to 15% of the DVT patient population. 7 As such, it is commonly believed that patients with these cancer types are at a very high risk of DVT. Nevertheless, these associations are largely derived from clinical trials evaluating antithrombotic agents in which approximately 20% of subjects have had an underlying malignancy and from autopsy studies in which mucin-producing adenocarcinomas, such as those of lung and colorectal origin, have been shown to be highly associated with venous thrombosis. In fact, few data exist regarding the incidence of symptomatic DVT in patients with these cancers, and there are even fewer reports in patients with lung cancer.
Because lung cancer, specifically non-small cell lung cancer (NSCLC), which constitutes 85% of all lung cancers, 8 is a major public health problem associated with a high incidence and case-fatality rate, specific and accurate estimates of DVT frequency are important in the care of these patients. To study the association between DVT and NSCLC, we investigated the risk of DVT in a well-defined cohort of patients with NSCLC, and we assessed clinical characteristics to identify those patients at high risk for DVT.
METHODS

Patient Population
General Hospital, a tertiary care hospital, between January 1997 and December 2004. The database contains prospectively collected information on all consecutive patients with lung cancer referred to the pulmonary oncology clinic since January 1997. It includes demographic and clinical information and is maintained by specialized oncology data managers and research assistants. It has been used by other researchers, including members of our research team, to answer clinical research questions. 9, 10 Patients were eligible to enter the cohort if they had a first diagnosis of histologically confirmed NSCLC and did not have a concurrent diagnosis of DVT at the time of the lung cancer diagnosis. Patients were excluded if they only briefly visited the SMBD-Jewish General Hospital pulmonary oncology clinic for diagnosis or therapy with no longterm follow-up, or if they had no recorded information. Patients exited the cohort on the earliest of the following dates: (1) at the end of the study period (December 31, 2004), (2) on the date of diagnosis of DVT, or (3) at the time of death.
DVT Diagnosis
We ascertained the occurrence of symptomatic DVT since diagnosis of NSCLC from the database, the patient's medical record, and the records of the vascular laboratory of the SMBD-Jewish General Hospital. The vascular laboratory receives and registers inpatient and outpatient requests for duplex venous ultrasonography and archives all duplex ultrasound reports that confirm a venous thrombosis. As a result, DVT occurrences that were ascertained from the database or from a patient's medical record were then confirmed with the vascular laboratory records. The patient's unique hospital number was used to link the database to the vascular laboratory. The following thrombotic events were excluded from the analysis: (1) thrombotic episodes identified in the database or in patient medical records that could not be confirmed by the vascular laboratory, and (2) a duplex ultrasound report indicating a superficial thrombophlebitis or chronic venous changes. Confirmation of an acute DVT by venous duplex ultrasonography was based on noncompressibility of the thrombosed vein with reduced or absent blood flow or direct visualization of a hyperechoic intraluminal thrombus. Each DVT was characterized with regard to its anatomic location (upper versus lower extremity) and, in the case of a lowerextremity DVT, proximal (popliteal-femor-iliac) versus distal (collecting calf veins) DVT.
Data Collection
From the database, we recorded (1) demographic data: date of birth, age at NSCLC diagnosis, and sex; (2) tumor characteristics: histologic classification and stage of tumor; and (3) clinical characteristics: Eastern Cooperative Oncology Group (ECOG) performance status at time of NSCLC diagnosis, and chemotherapy and surgery received. Information on the date of diagnosis and anatomic location of the DVT was retrieved from the vascular laboratory records. Information on the date of death was retrieved from the database and patient medical records.
Statistical Analysis
Data were analyzed using SAS/STAT software, version 8.2 for Windows. For each patient, person-years of follow-up were counted from the date of lung cancer diagnosis until the date of the DVT, the date of death, or the end of the study period. By dividing the number of cases of DVT by the number of person-years, we computed the incidence rate of DVT. Simple descriptive statistics (means with standard deviation; proportions) were used to summarize demographic, clinical, and tumor characteristics of the cohort. Comparisons between patients with DVT and those without DVT were made using Fisher's exact test, Student's t test, or 2 test, as appropriate. A two-sided p value Ͻ0.05 was considered statistically significant.
To assess which characteristics predicted the occurrence of DVT, eight variables (age dichotomized at 65 years of age, sex, ECOG performance, tumor type, clinical stage, chemotherapy, surgery) were assessed using Poisson regression modeling. 11 After assessing for collinearity among the variables (correlation coefficient Ͼ0.6 indicated an important correlation) and statistically significant interactions between the variables (Breslow-Day test for homogeneity), predictors identified in the univariate analysis were included in different models and compared to determine confounders, and the Akaike information criterion was used to select the best model to explain the risk of DVT. All p values were determined using two-tailed tests of significance, and 95% confidence intervals (CI) are provided.
Ethical Issues and Confidentiality
The study protocol was approved by the review ethics committee of the SMBD-Jewish General Hospital. Because the study used data maintained by the pulmonary oncology division, no individual consent was obtained. Only data relevant to the study was provided for analyses.
RESULTS
From January 1997 to December 2004, 493 patients with NSCLC were included in the study. We excluded 40 patients because they briefly attended the clinic for diagnosis or therapy, four patients because a primary diagnosis of lung cancer could not be histologically confirmed, and six patients because of non-lung cancer metastases. Among the 493 patients, a total 634 person-years were accrued and 67 DVT episodes were confirmed. The incidence density of DVT was 110 (95% CI ϭ 80, 130) per 1000 person-years. The overall incidence of DVT was 13.6%, with 64% of patients developing the DVT within 6 months of diagnosis. All DVT episodes occurred in the lower extremity, with 32 (47.8%) episodes limited to the distal leg veins and 35 (52.2%) involving the proximal leg veins. Table 1 presents the characteristics of the study population. Overall, 60% were male, and the mean age at cancer diagnosis was 65 years. Approximately 60% of the tumors were adenocarcinoma, and 25% were of squamous-cell origin. At the time of diagnosis, 72% of patients had stage IIIb or greater disease. In all, 246 (49.9%) study patients received chemotherapy. None of the patients received a vascular endothelial growth factor inhibitor, which, in combination with chemotherapy, is associated with an increased risk of thrombosis. 12 Table 2 compares clinical and tumor characteristic in patients with and without DVT. Advanced cancer stage (ՆIIIb) was more frequent in patients with DVT compared with patients without DVT. This difference was statistically significant. Distribution of other characteristics was similar between the two groups. Of the 31 patients who received chemotherapy before a diagnosis of DVT, 17 (54.8%) patients developed the DVT during a course of chemotherapy, and 14 (45.2%) patients were diagnosed, on average, 4.1 months after completion of chemotherapy. Eight of the 67 DVT events (11.9%) were observed in patients who had had surgical procedures, with a median time to DVT of 4.2 months.
The best-fit multivariate model, using the eight characteristics examined as potential predictors of DVT in the univariate analysis ( 
DISCUSSION
The risk of DVT in this large-cohort study of 493 patients with NSCLC was high, with an estimated incidence of 110 per 1000 patient-years, which is 100-fold higher than the thrombosis risk in the general population (1-2 per 1000 patient-years). 13 Patients with lung cancer have always been assumed to be at a high risk of venous thrombosis, mostly because numerous antithrombotic trials and cohort studies of patients with venous thrombosis have demonstrated that lung cancer is common in these patients. 14, 15 Nevertheless, few studies have reported on the actual incidence or absolute risk of venous thrombosis in cancer patients, and, to our knowledge, only six previous studies have described the risk of venous thrombosis in patients with lung cancer.
In the earliest such study, Ziomek and colleagues 16 performed serial venous duplex scanning on 77 patients undergoing thoracotomy, of whom 50 patients (65%) had NSCLC; they report an overall incidence of venous thrombosis (including pulmonary embolism) of 26% and a DVT incidence (including distal DVT) of 19.5% in the 30-day postoperative period. Unlike our study, this was an entirely surgical cohort, and thrombotic events included asymptomatic DVT. This may explain the higher incidence of DVT compared with that observed in our study. In a more recent Medicare database study of more than 1 million cancer patients hospitalized during 1988 to 1990, 61 venous thrombosis events, which included pulmonary embolism, were observed per 10,000 lung cancer patients during 183 days of follow-up, for a calculated annual incidence of 12.2 per 1000 person-years. 3 Unlike our study, thrombotic events were not objectively defined; instead, they were identified by discharge diagnoses, which may not accurately reflect events that occurred during hospitalization. Moreover, Medicare data have been shown to underreport hospitalizations by 10% to 27%. 17 As a result, there may have been incomplete ascertainment of thrombosis events, which may explain the much lower incidence in this study compared with our observed rate.
In their prospective cohort of 537 patients with NSCLC, Blom and colleagues 18 observed 39 venous thrombosis events, including pulmonary embolism, in 879 years of follow-up, for an overall incidence of venous thrombosis of 44 cases per 1000 patient-years. Once again, the lower incidence in comparison with our reported incidence of 110 per 1000 patient-years may be explained in part by the difference in verification of venous thrombosis. Unlike our study, thrombotic episodes were not objectively verified; instead, they were ascertained either by reviewing medical records of hospitals and anticoagulation clinics or by consulting the general practitioner. Blom and colleagues 19 also have described the incidence of venous thrombosis among patients with cancer, using linked records of a cancer registry and an anticoagulation clinic database in the Netherlands; they report an incidence of 27.6 per 1000 patient-years among the 9336 patients with lung cancer. Nevertheless, as described by the authors, there were several limitations to the study, including the fact that incident cases of venous thrombosis were not completely captured because the indication for anticoagulation was not always registered by the clinics, and furthermore, patients diagnosed with venous thrombosis may not have been referred to the anticoagulation clinics for treatment. For example, because of the limited performance of compression ultrasound to diagnose distal DVT and the relatively low risk of proximal extension and embolization of isolated distal DVT, several diagnostic centers do not systematically screen the calf veins of patients referred for DVT investigation, and in centers where isolated distal DVT is diagnosed, it may not always be treated. 20 Hence, the inclusion of distal DVT episodes in our study may account for the higher DVT incidence compared with that reported in the literature. Although data from prospective cohort studies of surgical and medical patients seem to suggest that the rate of proximal extension and embolization of isolated distal DVT is low (anywhere between 0.9% and 5.7% 20 ), the clinical significance of distal DVT in cancer patients has not been well studied.
Finally, Numico and colleagues 21 prospectively observed 108 patients with stage III or IV NSCLC for an average period of 8.7 months, recording a total of 22 symptomatic vascular events among 19 patients (17.6%, 95% CI [10.3, 24 .8%]). Twelve of these events were venous thrombotic episodes (including pulmonary embolism) among 12 patients, for a calculated cumulative risk of 11%. Similarly, in a post hoc analysis using data from two phase III trials of prinomastat (matrix metalloproteinase inhibitor) versus placebo with concomitant chemotherapy in patients with advanced NSCLC (stage IIIb or IV), an overall venous thrombosis incidence of 92.8 (95% CI [66. 8, 118.7] ) per 1000 patient-years was observed, with a "background" (patientyears without prinomastat or central venous catheter) incidence of 68 (95% CI [45.24, 90.8]) per 1000 patient-years. 22 In both studies, a relatively high risk of thrombosis was observed among patients with advanced-stage NSCLC. Our study population largely comprised patients with advancedstage NSCLC (72% had stage IIIb or IV), and several studies have shown a direct association between cancer stage and thrombosis risk. 1, 23 Our data show that patients with stage IIIb or IV NSCLC are, on average, 2.6 times more likely to be diagnosed with DVT than are patients with less-advancedstage NSCLC. We hypothesize that patients with advanced cancer are more hypercoagulable than patients with localized cancer and are more likely to suffer complications, such as immobility, that increase the risk of thrombosis. In addition to advanced stage, male sex independently predicted the occurrence of DVT in our study population. Although population-based prospective studies have shown sex-related differences in the epidemiology of venous thrombosis-specifically, men have a 1.2-to 3.6-fold increased risk of recurrence after an initial thrombosis episode 24 -26 -there have been no published studies in support of a higher risk of DVT in men with cancer versus women with cancer. Nevertheless, our results may have been confounded by unmeasured risk factors for venous thrombosis that may be more prevalent in men than in women. For example, compared with women, men are more likely to be diagnosed with conditions such as cardiovascular disease; hence, they are more likely to be hospitalized. This finding also may have been spurious, because the lower limit of the CI was close to unity.
We did not find an increased risk of DVT related to surgery, likely because adequate prophylaxis was given to patients who underwent surgery. Nonetheless, we cannot exclude the possibility that the sample size may have been too small to detect a clinically significant association. Also, exposure to chemotherapy did not predict the occurrence of DVT in our study. Nevertheless, we did not assess the risk of DVT during the period of chemotherapy, which has been reported in patients with lung, breast, and gynecological cancer to be increased. 19, 27, 28 Finally, upper-extremity DVT events were not observed, likely because of the low prevalence of central venous catheter use in our study population.
Our study had important limitations. First, as a result of its retrospective nature, our study lacked information on other potentially important predictors of DVT, such as a past history of venous thrombosis and use of anticoagulant medications. Second, the number of DVT events may have been underestimated because we could only detect patients with symptomatic and objectively verified DVT, and we may have missed patients who were treated for probable DVT without performing objective testing or who were diagnosed with DVT by other diagnostic modalities, such as nonduplex compression ultrasound, venography, computed tomographic angiography, and magnetic resonance imaging. Nevertheless, this number is likely very small, because nonduplex compression ultrasound and venography are rarely performed in our institution, and computed tomography angiography and magnetic resonance imaging specifically for the diagnosis of venous thrombosis were not yet in use in our institution during the study period. Finally, information on pulmonary embolism was not reliably recorded in the pulmonary oncology database, and linkage to nuclear medicine and radiology departmental databases was not possible. As a result, we could not report on the incidence of pulmonary embolism in our cohort.
In conclusion, our study shows that the occurrence of DVT in patients with NSCLC is more common than has been reported previously. Moreover, like others, we have confirmed that advanced stage was a strong predictor of DVT. Although anticoagulant, prophylactic therapies are well established in patients with cancer, including lung cancer, who are hospitalized and/or undergoing surgery, 29 the findings from this study support the rationale for an evaluation of anticoagulant DVT prophylaxis beyond the postoperative period and time of hospitalization. In particular, clinical trials should be conducted to assess the efficacy and safety of prophylactic anticoagulation in patients with NSCLC, particularly advanced-stage lung cancer. Also, the effects on mortality and quality of life should be addressed, because the role of low-molecular weight heparins in improving the survival of cancer patients is being investigated continuously. 30 -32 Finally, prospective studies are needed to better evaluate the effect of gender on the risk of DVT among patients with NSCLC.
